CN107541361A - 用以处理隐形眼镜的溶液 - Google Patents
用以处理隐形眼镜的溶液 Download PDFInfo
- Publication number
- CN107541361A CN107541361A CN201610587158.2A CN201610587158A CN107541361A CN 107541361 A CN107541361 A CN 107541361A CN 201610587158 A CN201610587158 A CN 201610587158A CN 107541361 A CN107541361 A CN 107541361A
- Authority
- CN
- China
- Prior art keywords
- solution
- contact lenses
- weight
- vitamin
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 30
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 30
- -1 isodecyl Chemical group 0.000 claims description 25
- 229930003779 Vitamin B12 Natural products 0.000 claims description 18
- 235000019163 vitamin B12 Nutrition 0.000 claims description 18
- 239000011715 vitamin B12 Substances 0.000 claims description 18
- 229940011671 vitamin b6 Drugs 0.000 claims description 16
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 15
- 235000019158 vitamin B6 Nutrition 0.000 claims description 15
- 239000011726 vitamin B6 Substances 0.000 claims description 15
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 13
- 239000004327 boric acid Substances 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 10
- 229930003270 Vitamin B Natural products 0.000 claims description 9
- 235000019156 vitamin B Nutrition 0.000 claims description 9
- 239000011720 vitamin B Substances 0.000 claims description 9
- 229950004354 phosphorylcholine Drugs 0.000 claims description 7
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- 229930003471 Vitamin B2 Natural products 0.000 claims description 6
- 235000019164 vitamin B2 Nutrition 0.000 claims description 6
- 239000011716 vitamin B2 Substances 0.000 claims description 6
- 229930003451 Vitamin B1 Natural products 0.000 claims description 5
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 5
- 229960002477 riboflavin Drugs 0.000 claims description 5
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 5
- 235000010374 vitamin B1 Nutrition 0.000 claims description 5
- 239000011691 vitamin B1 Substances 0.000 claims description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- 229960003495 thiamine Drugs 0.000 claims description 4
- 229930003537 Vitamin B3 Natural products 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000019160 vitamin B3 Nutrition 0.000 claims description 3
- 239000011708 vitamin B3 Substances 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 2
- CZCSLHYZEQSUNV-UHFFFAOYSA-N [Na].OB(O)O Chemical compound [Na].OB(O)O CZCSLHYZEQSUNV-UHFFFAOYSA-N 0.000 claims 1
- 238000005660 chlorination reaction Methods 0.000 claims 1
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 claims 1
- 238000004140 cleaning Methods 0.000 abstract description 7
- 208000003464 asthenopia Diseases 0.000 abstract description 6
- NJNWCIAPVGRBHO-UHFFFAOYSA-N 2-hydroxyethyl-dimethyl-[(oxo-$l^{5}-phosphanylidyne)methyl]azanium Chemical group OCC[N+](C)(C)C#P=O NJNWCIAPVGRBHO-UHFFFAOYSA-N 0.000 abstract 1
- 229910017053 inorganic salt Inorganic materials 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 238000002791 soaking Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 28
- 235000002639 sodium chloride Nutrition 0.000 description 21
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 18
- 239000007788 liquid Substances 0.000 description 17
- 230000003020 moisturizing effect Effects 0.000 description 17
- 229920001577 copolymer Polymers 0.000 description 15
- 239000000178 monomer Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 12
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 11
- 210000001508 eye Anatomy 0.000 description 11
- 229920001519 homopolymer Polymers 0.000 description 11
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 8
- 102100026735 Coagulation factor VIII Human genes 0.000 description 8
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 8
- NLAIHECABDOZBR-UHFFFAOYSA-M sodium 2,2-bis(2-methylprop-2-enoyloxymethyl)butyl 2-methylprop-2-enoate 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoate Chemical compound [Na+].CC(=C)C([O-])=O.CC(=C)C(=O)OCCO.CCC(COC(=O)C(C)=C)(COC(=O)C(C)=C)COC(=O)C(C)=C NLAIHECABDOZBR-UHFFFAOYSA-M 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 239000000376 reactant Substances 0.000 description 7
- YHHSONZFOIEMCP-UHFFFAOYSA-N 2-(trimethylazaniumyl)ethyl hydrogen phosphate Chemical compound C[N+](C)(C)CCOP(O)([O-])=O YHHSONZFOIEMCP-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 238000005227 gel permeation chromatography Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000004743 Polypropylene Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000003292 glue Substances 0.000 description 5
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 5
- 229920001155 polypropylene Polymers 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000010148 water-pollination Effects 0.000 description 5
- XQRBWCCHHZFDGD-UHFFFAOYSA-M 2-hydroxyethyl-dimethyl-[(oxo-lambda5-phosphanylidyne)methyl]azanium 2-(trimethylazaniumyl)ethyl phosphate Chemical group C[N+](C)(C)CCOP(=O)([O-])[O-].C[N+](C)(CCO)C#P=O XQRBWCCHHZFDGD-UHFFFAOYSA-M 0.000 description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 229940010747 sodium hyaluronate Drugs 0.000 description 4
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 3
- ZSZRUEAFVQITHH-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CC(=C)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C ZSZRUEAFVQITHH-UHFFFAOYSA-N 0.000 description 3
- COCLLEMEIJQBAG-UHFFFAOYSA-N 8-methylnonyl 2-methylprop-2-enoate Chemical compound CC(C)CCCCCCCOC(=O)C(C)=C COCLLEMEIJQBAG-UHFFFAOYSA-N 0.000 description 3
- OKKRPWIIYQTPQF-UHFFFAOYSA-N Trimethylolpropane trimethacrylate Chemical compound CC(=C)C(=O)OCC(CC)(COC(=O)C(C)=C)COC(=O)C(C)=C OKKRPWIIYQTPQF-UHFFFAOYSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 3
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- GMSCBRSQMRDRCD-UHFFFAOYSA-N dodecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)=C GMSCBRSQMRDRCD-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- RTDXMJJSUVCSKB-RUCXOUQFSA-N (2s)-2-azanyl-4-sulfanyl-butanoic acid Chemical compound OC(=O)[C@@H](N)CCS.OC(=O)[C@@H](N)CCS RTDXMJJSUVCSKB-RUCXOUQFSA-N 0.000 description 1
- LKGZXHMACFZOBP-UHFFFAOYSA-N 1-diethoxyphosphoryl-4-methylsulfanylbenzene Chemical compound CCOP(=O)(OCC)C1=CC=C(SC)C=C1 LKGZXHMACFZOBP-UHFFFAOYSA-N 0.000 description 1
- QRIMLDXJAPZHJE-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)CO QRIMLDXJAPZHJE-UHFFFAOYSA-N 0.000 description 1
- YOIZTLBZAMFVPK-UHFFFAOYSA-N 2-(3-ethoxy-4-hydroxyphenyl)-2-hydroxyacetic acid Chemical compound CCOC1=CC(C(O)C(O)=O)=CC=C1O YOIZTLBZAMFVPK-UHFFFAOYSA-N 0.000 description 1
- WDQMWEYDKDCEHT-UHFFFAOYSA-N 2-ethylhexyl 2-methylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)C(C)=C WDQMWEYDKDCEHT-UHFFFAOYSA-N 0.000 description 1
- RWHRFHQRVDUPIK-UHFFFAOYSA-N 50867-57-7 Chemical compound CC(=C)C(O)=O.CC(=C)C(O)=O RWHRFHQRVDUPIK-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- DFXLOZOEAQFNPJ-UHFFFAOYSA-N CCC(C[N+](C)(C)C)(OC(C=C)=O)OP([O-])(O)=O Chemical group CCC(C[N+](C)(C)C)(OC(C=C)=O)OP([O-])(O)=O DFXLOZOEAQFNPJ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000012986 chain transfer agent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- URMNHHAUVFEMIG-UHFFFAOYSA-N ethyl 6-methyl-2-oxo-4-phenyl-3,4-dihydro-1h-pyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=C(C)NC(=O)NC1C1=CC=CC=C1 URMNHHAUVFEMIG-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- 229940088644 n,n-dimethylacrylamide Drugs 0.000 description 1
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002946 poly[2-(methacryloxy)ethyl phosphorylcholine] polymer Polymers 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F130/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal
- C08F130/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing phosphorus
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/0005—Other compounding ingredients characterised by their effect
- C11D3/0078—Compositions for cleaning contact lenses, spectacles or lenses
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/02—Inorganic compounds ; Elemental compounds
- C11D3/04—Water-soluble compounds
- C11D3/042—Acids
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/02—Inorganic compounds ; Elemental compounds
- C11D3/04—Water-soluble compounds
- C11D3/046—Salts
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/168—Organometallic compounds or orgometallic complexes
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/36—Organic compounds containing phosphorus
- C11D3/365—Organic compounds containing phosphorus containing carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/37—Polymers
- C11D3/3746—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
- C11D3/3784—(Co)polymerised monomers containing phosphorus
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
- C11D7/02—Inorganic compounds
- C11D7/04—Water-soluble compounds
- C11D7/10—Salts
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Ophthalmology & Optometry (AREA)
- Eyeglasses (AREA)
- Detergent Compositions (AREA)
Abstract
本发明公开了一种用以处理隐形眼镜的溶液,该溶液包含了具有磷酸胆碱基的聚合物约0.01~1.0重量份、无机盐约0.01~1重量份及水约100重量份。聚合物的数均分子量为约4,000至约1,000,000道尔顿(Dalton),且聚合物具有式(I)的结构:在式(I)中,m为正整数,n为0或正整数,R为C2~C12烷基或C2~C12羟烷基,其中当n为正整数时,m/n大于1。利用此用以处理隐形眼镜的溶液浸泡或清洁隐形眼镜,将能提升隐形眼镜的保湿度而使得镜片表面不容易变干涩,并能够降低配戴所致的眼部疲劳。
Description
技术领域
本发明涉及一种用以处理隐形眼镜的溶液。
背景技术
软性隐形眼镜为市面上普遍存在的产品,其被包装于含有保存液的聚丙烯泡壳(polypropylene blister)包装中以进行销售。保存液通常为生理食盐水缓冲液,除了包含氯化钠及其他无机盐以外,一般还包含界面活性剂或保湿剂,以维持隐形眼镜的保湿度,并避免隐形眼镜黏贴于气泡状构造的内表面。
以隐形眼镜的功能而言,除了要能矫正视觉敏锐度之外,其配戴舒适度对于消费者的偏好亦具有重要影响。因此,隐形眼镜业者多半以提升隐形眼镜舒适度为目标。隐形眼镜舒适度受许多因素影响,而配戴的不适可能来自于镜片过硬、保湿度不足而使得镜片表面容易变干涩、表面粗糙或镜片设计不良。
镜片的保湿度及舒适度除了取决于镜片材质,更与镜片的保存液、甚至清洁液成分相关。除了在溶液中添加亲水性物质以增加镜片的保水性使得镜片表面不容易变干涩,更需要一些营养素以增进人眼健康。然而,市面上缺乏同时含有亲水性物质及营养素的隐形眼镜处理溶液。
因此,目前需要一种同时含有亲水性物质及营养素的隐形眼镜处理溶液,除了增加隐形眼镜的保湿度,以及让隐形眼镜片表面不容易变干之外,更能促进眼睛健康,从而降低长时间配戴所致的眼部疲劳,并提升镜片配戴的舒适度。
发明内容
本发明提供一种用以处理隐形眼镜的溶液,其包含具有磷酸胆碱(phosphorylcholine)基的聚合物约0.01~1.0重量份、无机盐约0.01~1重量份及水约100重量份。聚合物的数均分子量为约4,000至约1,000,000道尔顿(Dalton),且聚合物具有式(I)的结构:
在式(I)中,m为正整数,n为0或正整数,R为C2~C12烷基或C2~C12羟烷基,其中当n为正整数时,m/n大于1。通过使用以处理隐形眼镜的溶液包含此亲水性聚合物,将能提升隐形眼镜的保湿度而使得镜片表面不容易变干涩并降低配戴所致的眼部疲劳。虽然根据专利文献记载,当亲水性高分子材料例如玻尿酸(hyaluronic acid)被添加在处理隐形眼镜的溶液时可达到镜片保湿的效果,在本发明中,我们发现受试者配戴浸泡过含磷酸胆碱(phosphorylcholine)基的聚合物的溶液的镜片,镜片表面不易变得干涩。
根据本发明一些实施例,用以处理隐形眼镜的溶液进一步包含维生素B,为约0.001~0.1重量份。根据本发明一些实施例,维生素B选自于由维生素B1、维生素B2、维生素B3、维生素B6及维生素B12所构成的群组。
根据本发明一些实施例,维生素B6为约0.01~0.1重量份。
根据本发明一些实施例,维生素B12为约0.001~0.1重量份。
根据本发明一些实施例,R为正丁基(n-butyl)、2-乙基己基(2-ethylhexyl)、异癸基(isodecyl)、月桂基(lauryl)、2-羟乙基(2-hydroxyethyl)或2,3-二羟基丙基(2,3-dihydroxypropyl)。
根据本发明一些实施例,无机盐包含氯化钠,而氯化钠为约0.1~1重量份。
根据本发明一些实施例,溶液还包含硼酸,硼酸为约0.1~1重量份。
根据本发明一些实施例,无机盐还包含硼酸钠,硼酸钠为约0.01~0.1重量份。
根据本发明一些实施例,溶液为用以保存隐形眼镜的溶液或用以清洁隐形眼镜的溶液。
利用此用以处理隐形眼镜的溶液浸泡或清洁隐形眼镜,将能提升隐形眼镜的保湿度而使得镜片表面不容易变干涩,并能够降低配戴所致的眼部疲劳。
具体实施方式
以下揭示本发明的多个实施方式,为明确说明起见,许多实务上的细节将在以下叙述中一并说明。然而,应了解到,这些实务上的细节不应用以限制本发明。也就是说,在本发明部分实施方式中,这些实务上的细节是非必要的。此外,文中所示的化学结构式将以简单示意的方式绘示。
在本文中,除非内文中对于冠词有所特别限定,否则“一”与“该”可泛指单一个或多个。将进一步理解的是,本文中所使用的“包含”、“包括”、“具有”及相似词汇,指明其所记载的特征、区域、整数、步骤、操作、元件和/或组件,但不排除其所述或额外的其一个或多个其它特征、区域、整数、步骤、操作、元件、组件,和/或其中的群组。
如前所述,镜片的保湿度及舒适度与镜片的保存液、甚至清洁液成分息息相关,因为保存液中的部分成分可在镜片的高温高压灭菌过程中进入镜片基材中或附着于镜片表面。同时,基于镜片的孔径、亲水性、以及镜片与保存液成分间的极性差异大小,保存液中不同成分于镜片表面的附着程度会有所不同。
虽然不同的水胶镜片可能具有相同的含水量,但因其可能由不同的单体组合所聚合而成,故会具有不同的交联密度。因此,保存液成分能否进入或穿透镜片的能力除了取决于这些成分的极性与分子量,还受到水胶镜片的交联密度高低所影响。
形成隐形眼镜常用的聚合物,可由具有端乙烯基可聚合单体(ethylenically-based polymerizable monomer)与含硅预聚物所聚合而成,包含N-乙烯基吡咯烷酮(N-vinyl pyrrolidone,NVP)、N,N-二甲基丙烯酰胺(N,N-dimethyl acrylamide,DMA)、2-甲基丙烯酰氧乙基磷酸胆碱(2-methacryloyloxyethyl phosphorylcholine,MPC)、不同种类的甲基丙烯酸烷酯(alkyl methacrylate)、及不同种类的甲基丙烯酸羟烷酯(hydroxyalkylmethacrylate)等。
不同端乙烯基可聚合单体的亲水性不同,而合适的端乙烯基可聚合单体所形成的聚合物由于具有亲水性,故亦可被加入用以处理镜片的溶液(包含用以保存隐形眼镜的溶液与用以清洁隐形眼镜的溶液)中,以提高镜片的保湿度。
然而,即使亲水性聚合物能增加镜片保湿度,但对于长时间配戴后镜片舒适度的维持效果仍有限。因此,除了在保存液或清洁液中加入亲水性聚合物,还需要额外成分让镜片表面不容易变干涩,以增加长时间配戴的舒适度。据此,本发明提供一种用以处理隐形眼镜的溶液,其包含具有磷酸胆碱(phosphorylcholine)基的聚合物,或同时包含此聚合物以及维生素B,以达到在维持镜片保湿度镜片表面不容易变干涩的同时降低眼睛疲劳的功效。
2-甲基丙烯酰氧乙基磷酸胆碱(2-methacryloyloxyethyl phosphorylcholine,MPC)具有磷酸胆碱基,而能够展现显著的亲水性,亦使其所形成的聚合物,不论是均聚物(homopolymer)及共聚物(copolymer),均具有高亲水性。
以均聚物而言,聚[2-甲基丙烯酰氧乙基磷酸胆碱](poly[2-methacryloyloxyethyl phosphorylcholine],poly-MPC)为带有高亲水性、且具有磷酸胆碱(phosphorylcholine)基的聚合物。以共聚物而言,由于甲基丙烯酸酯(methacrylate)亦为亲水性基团,故MPC与甲基丙烯酸酯单体所共聚合形成的共聚物会具有更显著的亲水性。因此,由MPC所形成的聚合物,不论是均聚物或共聚物,若被加入隐形眼镜的处理溶液中,皆可有效地增加镜片保湿度。
另一方面,维生素B,尤其是维生素B6(比哆醇,pyridoxine)及维生素B12(钴胺素,cobalamin),对于人眼的健康度具有显著的促进效果。
维生素B6除了调节多种含硫胺基酸的代谢、促进肝醣分解、维持钠、钾离子平衡、促进红血球生成之外,更增进免疫功能并促进细胞生长。此外,维生素B6亦促进辅脢-A(co-enzyme A)的合成及维生素B12的吸收,故能调控脑细胞代谢,而具有强化神经系统、稳定情绪的效果。
维生素B12与叶酸(folic acid)共同作用以调控高半胱胺酸(homocysteine)浓度,避免高半胱胺酸浓度过高所致的心脏病及中风风险,甚至减低骨质疏松及阿兹海默症的可能性。另外,维生素B12对于神经的正常功能亦具有关键影响,并被指出能有效减缓眼部疲劳。
另外,除了维生素B6及B12,维生素B1、B2及B3亦对于神经及眼睛健康有所影响:维生素B1及维生素B3(烟碱酸)可避免眼球颤抖、视觉迟钝、或眼睛疲劳等;而维生素B2则可避免眼睛干涩、眼球结膜充血、畏光、发痒、疲劳、甚至视神经炎或角膜炎。因此,本发明的用以处理隐形眼镜的溶液可包含维生素B6、B12、B1、B2、B3或其组合,以促进眼睛的舒适度。
具有磷酸胆碱(phosphorylcholine)基的聚合物及维生素B可停留于镜片表面或由镜片基材释出,除了使得镜片表面高度保湿而降低长时间配戴所致干燥外,维生素B6及B12更能同时滋养双眼。
因此,本发明提供一种用以处理隐形眼镜的溶液,包含了具有磷酸胆碱(phosphorylcholine)基的聚合物约0.01~1.0重量份、无机盐约0.01~1重量份及水约100重量份。聚合物的数均分子量为约4,000至约1,000,000道尔顿(Dalton),且聚合物具有式(I)的结构:
在式(I)中,m为正整数,n为0或正整数,R为C2~C12烷基或C2~C12羟烷基,其中当n为正整数时,m/n大于1。
当n为0时,此聚合物为具有磷酸胆碱基的均聚物,即聚(2-甲基丙烯酰氧乙基磷酸胆碱)(poly(2-methacryloyloxyethyl phosphorylcholine),poly-MPC)。当n为正整数时,此聚合物为具有磷酸胆碱基的共聚物。
本发明的共聚物可由2-甲基丙烯酰氧乙基磷酸胆碱(MPC)与甲基丙烯酸酯(methacrylic acid ester)共聚而成。举例来说,甲基丙烯酸酯可为甲基丙烯酸烷基酯或甲基丙烯酸羟烷基酯。甲基丙烯酸烷基酯具有C2~C12烷基,其可为甲基丙烯酸正丁酯(n-butyl methacrylate,BMA)、甲基丙烯酸-2-乙基己酯(2-ethylhexyl methacrylate,EHMA)、甲基丙烯酸异癸酯(isodecyl methacrylate,IDMA)或甲基丙烯酸月桂酯(laurylmethacrylate,LMA)。甲基丙烯酸羟烷基酯具有C2~C12羟烷基,其可为甲基丙烯酸羟乙酯(2-hydroxyethyl methacrylate,HEMA)或甲基丙烯酸-2,3-二羟基丙酯(2,3-dihydroxypropyl methacrylate,DHPM)。因此可知,在具有式(I)的结构的聚合物中,R可为正丁基(n-butyl)、2-乙基己基(2-ethylhexyl)、异癸基(isodecyl)、月桂基(lauryl)、2-羟乙基(2-hydroxyethyl)或2,3-二羟基丙基(2,3-dihydroxypropyl)。
在本发明一些实施例中,用以处理隐形眼镜的溶液进一步包含维生素B,为约0.001~0.1重量份。在本发明一些实施例中,维生素B选自于由维生素B1、维生素B2、维生素B3、维生素B6及维生素B12所构成的群组。在本发明一些实施例中,维生素B6为约0.01~0.1重量份。在本发明一些实施例中,维生素B12为约0.001~0.1重量份。
在一些实施例中,当用以处理隐形眼镜的溶液中含有维生素B12时,该溶液呈现粉红色。由于部分的维生素B12会停留于镜片表面或进入镜片基材中,故镜片亦会呈现些微粉红色。粉红色的深浅取决于维生素B12的含量多少。
在本发明一些实施例中,无机盐包含氯化钠,且氯化钠为约0.1~1重量份。约0.1~1重量份的氯化钠溶于约100重量份的水可形成生理食盐水溶液。在一些实施例中,除了氯化钠,用以处理隐形眼镜的溶液中还包含硼酸,而硼酸为约0.1~1重量份。在另一些实施例中,无机盐还包含硼酸钠,而硼酸钠为约0.01~0.1重量份。硼酸及硼酸钠除了能协助调节溶液的pH值,更具有良好的抗菌功能。
在一些实施例中,本发明的用以处理隐形眼镜的溶液为用以保存隐形眼镜的溶液(即隐形眼镜保存液)或用以清洁隐形眼镜的溶液(即隐形眼镜清洁液)。在一些实施例中,本发明的用以处理隐形眼镜的溶液亦可选择性地包含界面活性剂和/或保湿剂。
本发明的用以处理隐形眼镜的溶液可应用于一般水胶镜片,但亦可透过调整聚合物的数均分子量及重量份比例,而可应用于不同的水胶镜片或硅水胶镜片上,而达到避免干眼并提供配戴者高舒适度的最适效果。
以下的实验例是用以详述本发明的特定态样,并使本发明所属技术领域中的技术人员得以实施本发明。以下的实验例不应用以限制本发明。
实验例1:具有磷酸胆碱基的均聚物-聚[2-甲基丙烯酰氧乙基磷酸胆碱](poly-MPC)的制备(实施例1A~1C):
此实验系将50g(0.169mole)的2-甲基丙烯酰氧乙基磷酸胆碱(MPC)及150mL的甲醇(methanol)加入三颈圆底烧瓶中,而三颈圆底烧瓶为连接回流冷凝器(refluxcondenser)。三颈圆底烧瓶中通入氮气,使MPC及甲醇在充满氮气的情况下进行搅拌10分钟直到溶解。接着,加入0.25g的偶氮二异丁腈(Azobisisobutyronitrile,AIBN)及0.0398g(0.509mmole)的2-巯基乙醇(2-mercaptoethanol)并加热至45℃且维持24小时。AIBN为聚合反应起始剂,其连接至MPC的甲基丙烯酰氧乙基(methacryloyloxyethyl)中与双键相连的碳原子,而引发自由基聚合反应(free radical polymerization)。2-巯基乙醇则为聚合链转移剂(chain transfer agent),其使得具有自由基的链状聚合物尾端终止反应,因而可用以控制聚合物的链长及分子量(数均分子量及重均分子量)。之后,甲醇会被去除而留存于烧瓶内,而所形成的poly-MPC(实施例1A),其会被压碎为粉状并置于1个100℃的烘箱中6小时以进行干燥。此实验约可产生45g的poly-MPC(实施例1A,MPC均聚物),其是以凝胶渗透色谱(GPC)进行分析,得到数均分子量(Mn)及重均分子量(Mw)。
数均分子量(Mn)是指具有不同单体数目(即不同链长)的每一聚合物的分子量乘以其数量比例后加总所得。重均分子量(Mw)则为每一聚合物的分子量乘以其重量占总重量比例后加总所得。由于不同单体数目的聚合物在计算Mn时权重皆一致,但较重(单体数目较多或较长链)的聚合物在计算Mw时权重较大,故聚合物的重均分子量(Mw)多半大于数均分子量(Mn),而Mw/Mn的比值为多分散性(polydispersity)。通常聚合反应所加入的2-mercaptoethanol量愈低,多分散性愈高,显示聚合物的分子量分布愈广,即聚合物所含单体数目的间的标准差愈大。
其它MPC均聚物的制备是采用上述方法,但所使用的各反应物用量有所不同。详细而言,MPC均聚物的制备是将59g(0.1999mole)的MPC及250mL的甲醇加入三颈圆底烧瓶中,而三颈圆底烧瓶为连接回流冷凝器。三颈圆底烧瓶中通入氮气,使MPC及甲醇在充满氮气的情况下进行搅拌10分钟直到溶解。接着,加入0.295g的AIBN及不同量的2-mercaptoethanol,分别为0.2343g(3mmole)或0.0398g(0.5mmole)的2-mercaptoethanol,再加热至45℃并维持24小时,以分别形成实施例1B或实施例1C。之后,甲醇会被去除而留存于烧瓶内,而所形成的poly-MPC(实施例1B、1C)则被置于1个100℃的烘箱中6小时以进行干燥。此实验所产生的MPC均聚物(实施例1B、1C)是以凝胶渗透色谱(GPC)进行分析。
GPC分析结果则显示实施例1A(透过50g MPC及0.5mmole的2-mercaptoethanol所形成)的数均分子量(Mn)为9,604,重均分子量(Mw)为31,935,而多分散性(polydispersity)为3.32。实施例1B(透过59g MPC及3mmole的2-mercaptoethanol所形成)的Mn为17,646,Mw为45,791,多分散性为2.595。实施例1C(透过透过59g MPC及0.5mmole的2-mercaptoethanol所形成)的Mn为47,121,Mw为206,531,多分散性为4.383。
实施例1A~1C具有如下式(II)的结构:
在式(II)中,m为正整数;而*为聚合反应的起始点,即连接AIBN的位置。
实验例2:具有磷酸胆碱基的共聚物的制备(实施例2A~2D):
MPC共聚物的制备亦采用上述方法,但是以不同种类的甲基丙烯酸羟烷基酯(hydroxyalkyl methacrylate)单体进行聚合,且所使用的各反应物用量有所不同。详细而言,MPC共聚物的制备包含将48g(0.163mole)的MPC、12g(0.092mole)的甲基丙烯酸羟乙酯(2-hydroxyethyl methacrylate,HEMA)及250mL的甲醇加入三颈圆底烧瓶中,而三颈圆底烧瓶为连接回流冷凝器。三颈圆底烧瓶中通入氮气,使MPC、HEMA及甲醇在充满氮气的情况下进行搅拌10分钟直到溶解。接着,加入0.295g的AIBN及不同量的2-mercaptoethanol,分别为0.932g(0.012mole)、0.2343g(3mmole)、或0.0469(0.06mmole)的2-mercaptoethanol,再加热至45℃并维持24小时,以分别形成实施例2A、2B或2C。之后,甲醇会被去除而留存于烧瓶内,而所形成的poly(MPC-co-HEMA)(MPC-HEMA共聚物,实施例2A~2C)则被置于1个100℃的烘箱中6小时以进行干燥。此实验所产生的MPC-HEMA共聚物(实施例2A~2C)是以凝胶渗透色谱(GPC)进行分析,得到数均分子量(Mn)及重均分子量(Mw)。
实施例2A(反应物:HEMA及0.012mole的2-mercaptoethanol)的Mn为13,341,Mw为21,438,多分散性为1.607。实施例2B(反应物:HEMA及3mmole的2-mercaptoethanol)的Mn为29,326,Mw为123,345,多分散性为4.206。实施例2C(反应物:HEMA及0.06mmole的2-mercaptoethanol)的Mn为106,978,Mw为721,246,多分散性为6.742。实施例2A~2C具有如下式(III)的结构:
在式(III)中,m、n为正整数,而*为聚合物反应的起始点,即连接AIBN的位置。
此外,依据上述方法,并将HEMA替换为5g(0.0352mole)的甲基丙烯酸正丁酯(n-butyl methacrylate,BMA),而AIBN用量调整为0.1g、2-mercaptoethanol用量调整为0.0615g(0.8mmole)、甲醇用量调整为284mL,则可制得poly(MPC-co-BMA)(MPC-BMA共聚物,实施例2D)。
实施例2D(反应物:BMA及0.8mmole的2-mercaptoethanol)的Mn为35,041,Mw为74,286,多分散性为2.12。实施例2D具有如下式(IV)的结构:
在式(IV)中,m、n为正整数,而*为聚合物反应的起始点,即连接AIBN的位置。
上述用以形成实施例1A~1C和2A~2D的反应物以及实施例1A~1C和2A~2D的分子量及多分散性皆列于下表1:
表1
实验例3:配制含有MPC均聚物及/或维生素B的镜片保存液:
此实验是透过在特定配方的生理食盐水溶液中选择性加入实施例1A(poly-MPC)、玻尿酸、维生素B6及/或维生素B12,而形成6种不同隐形眼镜保存液(比较例3A~3B及实施例3C~3F)。比较例3A~3B及实施例3C~3F的配方如下:
比较例3A:包含氯化钠0.708%(w/w)、硼酸0.470%(w/w)、硼酸钠0.05%(w/w),而溶剂为水。
比较例3B:包含氯化钠0.708%(w/w)、硼酸0.470%(w/w)、硼酸钠0.05%(w/w)及玻尿酸(HA,数平均分子量为100,000),0.10%(w/w),而溶剂为水。
实施例3C:包含氯化钠0.708%(w/w)、硼酸0.470%(w/w)、硼酸钠0.05%(w/w)及实施例1A(poly-MPC)0.10%(w/w),而溶剂为水。
实施例3D:包含氯化钠0.708%(w/w)、硼酸0.470%(w/w)、硼酸钠0.05%(w/w)、0.005%(w/w)维生素B12及实施例1A(poly-MPC)0.10%(w/w),而溶剂为水。
实施例3E:包含氯化钠0.708%(w/w)、硼酸0.470%(w/w)、硼酸钠0.05%(w/w)、0.005%(w/w)维生素B12、0.03%(w/w)维生素B6及实施例1A(poly-MPC)0.10%(w/w),而溶剂为水。
实施例3F:包含氯化钠0.708%(w/w)、硼酸0.470%(w/w)、硼酸钠0.05%(w/w)、0.03%(w/w)维生素B6及实施例1A(poly-MPC)0.10%(w/w),而溶剂为水。
实验例4:经不同镜片保存液处理的Etafilcon A镜片:
此实验将Etafilcon A镜片分别浸于比较例3A~3B及实施例3C~3F的保存液中。用以形成Etafilcon A镜片的单体组成包含甲基丙烯酸羟乙酯(2-hydroxyethylmethacrylate,HEMA)、甲基丙烯酸(methacrylic acid,MAA)、乙二醇二甲基丙烯酸酯(ethylene glycol dimethacrylate,EGDMA)、三羟甲基丙烷三甲基丙烯酸酯(1,1,1-trimethylolpropane trimethacrylate,TMPTMA)、以及抗紫外光(UV)单体2-[3-(2H-苯并三唑-2-基)-4-羟基苯基]乙基2-甲基丙烯酸酯(2(2-hydroxy-5-methacryloxyethylphenyl)-2H-benzotriazole)约0.8%。此单体组成物于模具中进行固化反应后可形成镜片。利用不同形状的聚丙烯模具进行注模法,可将镜片设计为具有不同曲度,将使得所制得的Etafilcon A镜片具有特定的矫正目标度数(target correctionpower)。镜片的矫正目标度数的范围为屈光度(dipoter)-2.00至-6.00,基弧(base curve,BC)8.5mm,而直径14.2mm。在经过适当的水化(hydration)过程后,Etafilcon A镜片是被包装于分别含有比较例3A~3B及实施例3C~3F的聚丙烯泡壳(polypropylene blister)包装中,并经过高温高压灭菌。这些完整制作的镜片除了有符合目标的参数与矫正度数之外,更具有58%的水含量。
实验例5:经不同保存液处理的Etafilcon A镜片的临床测试:
在经过适当法规程序后,对于分别经比较例3A(不含poly-MPC)、比较例3B(含玻尿酸)及实施例3D(含有poly-MPC)处理的Etafilcon A镜片进行临床测试。超过30名受试者被指定于温湿度控制的空调环境(25℃,湿度60%)中配戴镜片10小时以上。测试方式为受试者先配戴浸于比较例3A的镜片1天,隔天再改为配戴浸于比较例3B的镜片1天,再隔天再改为配戴浸于实施例3D的镜片1天,以如此交替配戴的方式对于镜片舒适度进行比较。
在配戴浸于比较例3A及比较例3B的镜片6小时后,皆有超过70%的受试者感到眼睛干燥。然而,在同样条件下,配戴浸于实施例3D中镜片的受试者中,无人感到眼睛干燥。如此结果明确显示保存液中的poly-MPC可有效维持镜片保湿度而避免干眼。此结果亦证明poly-MPC的保湿抗干燥效果比玻尿酸好很多,因此,由MPC所形成的共聚物亦能有效维持镜片保湿度,因而提升使用者的配戴舒适度。并且,即使Etafilcon A镜片中含有抗紫外光单体,由MPC所形成的共聚物亦能有效维持镜片保湿度,并提升使用者的配戴舒适度。
虽然本发明已以实施方式说明如上,但其它实施方式亦有可能。因此,本发明的精神与范围并不限定于此处实施方式所含的叙述。
任何本行业的技术人员,在不脱离本发明的精神和范围内,当可作各种的变动与润饰,因此本发明的保护范围当视权利要求所界定者为准。
Claims (10)
1.一种用以处理隐形眼镜的溶液,其特征在于,所述用以处理隐形眼镜的溶液包含:
具有磷酸胆碱基的聚合物,为约0.01~1.0重量份,所述聚合物的数均分子量为约4,000至约1,000,000道尔顿,且所述聚合物具有式(I)的结构:
在式(I)中,m为正整数,n为0或正整数,R为C2~C12烷基或C2~C12羟烷基,其中当n为正整数时,m/n大于1;
无机盐,为约0.01~1重量份;以及
水,为约100重量份。
2.如权利要求1所述的用以处理隐形眼镜的溶液,其特征在于,所述溶液进一步包含维生素B,为约0.001~0.1重量份。
3.如权利要求2所述的用以处理隐形眼镜的溶液,其特征在于,所述维生素B是选自于由维生素B1、维生素B2、维生素B3、维生素B6及维生素B12所构成的群组。
4.如权利要求3所述的用以处理隐形眼镜的溶液,其特征在于,所述维生素B6为约0.01~0.1重量份。
5.如权利要求3所述的用以处理隐形眼镜的溶液,其特征在于,所述维生素B12为约0.001~0.1重量份。
6.如权利要求1所述的用以处理隐形眼镜的溶液,其特征在于,R为正丁基、2-乙基己基、异癸基、月桂基、2-羟乙基或2,3-二羟基丙基。
7.如权利要求1所述的用以处理隐形眼镜的溶液,其特征在于,所述无机盐包含氯化钠,所述氯化钠为约0.1~1重量份。
8.如权利要求7所述的用以处理隐形眼镜的溶液,所述溶液还包含硼酸,所述硼酸为约0.1~1重量份。
9.如权利要求7所述的用以处理隐形眼镜的溶液,所述无机盐还包含硼酸钠,所述硼酸钠为约0.01~0.1重量份。
10.如权利要求1或2所述的用以处理隐形眼镜的溶液,所述溶液为用以保存隐形眼镜的溶液或用以清洁隐形眼镜的溶液。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW105120216A TWI634205B (zh) | 2016-06-27 | 2016-06-27 | 用以處理隱形眼鏡之溶液 |
TW105120216 | 2016-06-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107541361A true CN107541361A (zh) | 2018-01-05 |
CN107541361B CN107541361B (zh) | 2021-05-18 |
Family
ID=57226787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610587158.2A Active CN107541361B (zh) | 2016-06-27 | 2016-07-25 | 用以处理隐形眼镜的溶液 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9925293B2 (zh) |
EP (1) | EP3263683A1 (zh) |
JP (1) | JP2018005208A (zh) |
CN (1) | CN107541361B (zh) |
RU (1) | RU2675260C2 (zh) |
TW (1) | TWI634205B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109957475A (zh) * | 2018-12-26 | 2019-07-02 | 上海卫康光学眼镜有限公司 | 一种含磷酸胆碱聚合物的隐形眼镜保存液 |
WO2019232717A1 (zh) * | 2018-06-06 | 2019-12-12 | 晶硕光学股份有限公司 | 眼科产品及其眼科组合物 |
CN110564519A (zh) * | 2018-06-06 | 2019-12-13 | 晶硕光学股份有限公司 | 眼科产品及其眼科组合物 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000098310A (ja) * | 1998-09-18 | 2000-04-07 | Nof Corp | コンタクトレンズ用溶液 |
JP2003005136A (ja) * | 2001-06-21 | 2003-01-08 | Nof Corp | コンタクトレンズ用洗浄剤 |
US20030186825A1 (en) * | 2000-08-22 | 2003-10-02 | Nobuo Nakabayashi | Contact lens wetting solution |
US20090100801A1 (en) * | 2007-10-23 | 2009-04-23 | Bausch & Lomb Incorporated | Packaging Solutions |
CN102670641A (zh) * | 2011-03-10 | 2012-09-19 | 晶硕光学股份有限公司 | 用于隐形眼镜的液态组合物 |
CN105492029A (zh) * | 2013-08-30 | 2016-04-13 | 日油株式会社 | 滴眼剂 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5300296A (en) * | 1989-11-06 | 1994-04-05 | Frank J. Holly | Antimicrobial agent for opthalmic formulations |
JP3069926B2 (ja) * | 1991-10-14 | 2000-07-24 | 日本油脂株式会社 | コンタクトレンズ用処理溶液 |
SG54134A1 (en) * | 1991-10-14 | 1998-11-16 | Nof Corp | Treating solution for contact lenses |
JPH10324634A (ja) | 1997-03-28 | 1998-12-08 | Rohto Pharmaceut Co Ltd | リン脂質類似重合体を含有する眼科用医薬組成物 |
JP4309974B2 (ja) * | 1998-05-21 | 2009-08-05 | 日油株式会社 | 眼科用製剤 |
JP4316739B2 (ja) * | 1998-08-31 | 2009-08-19 | 日油株式会社 | コンタクトレンズ用処理溶液 |
JP4536175B2 (ja) * | 1998-09-18 | 2010-09-01 | 日油株式会社 | 防腐剤組成物 |
JP2000206471A (ja) * | 1999-01-08 | 2000-07-28 | Nof Corp | ハ―ドコンタクトレンズ用洗浄溶液 |
JP2000239696A (ja) * | 1999-02-22 | 2000-09-05 | Nof Corp | コンタクトレンズ用処理溶液 |
JP2000347141A (ja) | 1999-06-02 | 2000-12-15 | Nof Corp | 含水性コンタクトレンズ用処理液 |
EP3045168A1 (en) * | 2000-11-08 | 2016-07-20 | FXS Ventures, LLC | Improved ophthalmic and contact lens solution |
US20070104744A1 (en) | 2000-11-08 | 2007-05-10 | Fxs Ventures, Llc | Ophthalmic and contact lens solutions containing forms of vitamin b |
IL156766A0 (en) * | 2001-01-09 | 2004-02-08 | Louis Johan Wagenaar | Procedure and composition of treatment and/or care of the eye |
US20090173045A1 (en) * | 2008-01-09 | 2009-07-09 | Yu-Chin Lai | Packaging Solutions |
WO2009091728A2 (en) * | 2008-01-14 | 2009-07-23 | Coopervision International Holding Company, Lp | Polymerizable contact lens formulations and contact lenses obtained therefrom |
WO2013128633A1 (ja) * | 2012-03-02 | 2013-09-06 | 日油株式会社 | コンタクトレンズ用ケア製剤及びパッケージング溶液 |
JP5707843B2 (ja) * | 2010-10-20 | 2015-04-30 | 日油株式会社 | コンタクトレンズ用ケア製剤及びパッケージング溶液 |
US9295747B2 (en) | 2010-10-20 | 2016-03-29 | Nof Corporation | Contact lens care preparation and packaging solution |
JP2015147759A (ja) * | 2014-01-08 | 2015-08-20 | 日油株式会社 | 点眼剤 |
-
2016
- 2016-06-27 TW TW105120216A patent/TWI634205B/zh active
- 2016-07-25 CN CN201610587158.2A patent/CN107541361B/zh active Active
- 2016-09-05 US US15/256,637 patent/US9925293B2/en active Active
- 2016-09-13 JP JP2016178729A patent/JP2018005208A/ja active Pending
- 2016-10-03 RU RU2016138838A patent/RU2675260C2/ru active
- 2016-10-25 EP EP16195567.9A patent/EP3263683A1/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000098310A (ja) * | 1998-09-18 | 2000-04-07 | Nof Corp | コンタクトレンズ用溶液 |
US20030186825A1 (en) * | 2000-08-22 | 2003-10-02 | Nobuo Nakabayashi | Contact lens wetting solution |
JP2003005136A (ja) * | 2001-06-21 | 2003-01-08 | Nof Corp | コンタクトレンズ用洗浄剤 |
US20090100801A1 (en) * | 2007-10-23 | 2009-04-23 | Bausch & Lomb Incorporated | Packaging Solutions |
CN102670641A (zh) * | 2011-03-10 | 2012-09-19 | 晶硕光学股份有限公司 | 用于隐形眼镜的液态组合物 |
CN105492029A (zh) * | 2013-08-30 | 2016-04-13 | 日油株式会社 | 滴眼剂 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019232717A1 (zh) * | 2018-06-06 | 2019-12-12 | 晶硕光学股份有限公司 | 眼科产品及其眼科组合物 |
CN110564519A (zh) * | 2018-06-06 | 2019-12-13 | 晶硕光学股份有限公司 | 眼科产品及其眼科组合物 |
CN109957475A (zh) * | 2018-12-26 | 2019-07-02 | 上海卫康光学眼镜有限公司 | 一种含磷酸胆碱聚合物的隐形眼镜保存液 |
Also Published As
Publication number | Publication date |
---|---|
EP3263683A1 (en) | 2018-01-03 |
TW201800570A (zh) | 2018-01-01 |
RU2016138838A3 (zh) | 2018-04-04 |
RU2675260C2 (ru) | 2018-12-18 |
US20170368221A1 (en) | 2017-12-28 |
RU2016138838A (ru) | 2018-04-04 |
TWI634205B (zh) | 2018-09-01 |
JP2018005208A (ja) | 2018-01-11 |
CN107541361B (zh) | 2021-05-18 |
US9925293B2 (en) | 2018-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6138827B2 (ja) | スルホン酸基を含むシリコーンポリマー | |
TWI554776B (zh) | 具有均勻電荷密度之醫學裝置及製造其之方法 | |
CN104350076B (zh) | 聚合物和纳米凝胶材料、及其制备和使用方法 | |
CN107541362A (zh) | 用以处理隐形眼镜的溶液及隐形眼镜的包装系统 | |
KR102295439B1 (ko) | 콘택트 렌즈 및 안내 렌즈용 (메트)아크릴아미드 중합체 | |
CN106716233B (zh) | 具有润湿性表面的水凝胶隐形镜片及其制备方法 | |
JP6974425B2 (ja) | 高濃度のポリアミドを含むシリコーンヒドロゲル | |
JP6718858B2 (ja) | 表面改質されたコンタクトレンズ及びその調製方法 | |
CN107541361A (zh) | 用以处理隐形眼镜的溶液 | |
US20180244911A1 (en) | Composition, contact lens coating agent, method for producing contact lens, and contact lens | |
US10160854B1 (en) | Hydrogel materials | |
KR20190025704A (ko) | 난시 교정을 위한 소프트 콘택트 렌즈 내의 증가된 강직도의 중심 광학부 | |
CN115710329A (zh) | 一种含依克多因的软性亲水接触镜及其制备方法 | |
CN1950460B (zh) | 包含无环聚酰胺的润湿性水凝胶 | |
US6559198B2 (en) | Fluorocarbon-sulfone hydrophilic contact lenses, optical medical devices and compositions thereof | |
KR101826909B1 (ko) | 높은 표면 친수성을 갖는 콘택트렌즈 | |
KR102545476B1 (ko) | Mpc를 이용한 기능성이 향상된 실리콘 하이드로겔 콘택트 렌즈의 제조 방법 | |
KR101311134B1 (ko) | 약물 서방성 의료용 디바이스 | |
US20220340759A1 (en) | Polymerizable absorbers of uv and high energy visible light |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |